FDA Panel Won't Back Approval Of Biogen's Alzheimer's Drug
A U.S. Food and Drug Administration advisory committee on Friday declined to recommend Biogen's Alzheimer's drug aducanumab for approval, saying the agency shouldn't be so quick to embrace the biotech company's...To view the full article, register now.
Already a subscriber? Click here to view full article